Comparison · NCT01046136-c7749352
Mucinex vs Placebo: Number of Patients With Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Mucinex vs Placebo: Number of Patients With Adverse Events. Trial comparisons, record NCT01046136-c7749352. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01046136-c7749352
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0638 | 0.0369 | 0.108 | wilson | |
| Risk in group 2 | 0.0317 | 0.0146 | 0.0675 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0321 | -0.0127 | 0.0797 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.01 | 0.771 | 5.25 | log | |
| Odds ratio, group 1 over group 2 | 2.08 | 0.764 | 5.66 | log | |
| Number needed to treat, for one more participant with the outcome on Mucinex than on Placebo | 31.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Mucinex | 2 X 600 MG TABLETS EVERY 12 HOURS FOR 7 DAYS | 12 | 188 | OG000 |
| Group 2 | Placebo | 2 TABLETS EVERY 12 HOURS FOR 7 DAYS | 6 | 189 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Adverse Events
- Description
- Total number of patients with adverse events that were possibly or probably related.
- Time frame
- 7 days
- Population
- All participants who received study medication, excluding participants who later returned all the dispensed study medication to the site unused.
Source ClinicalTrials.gov
Trial
- Title
- Mucinex Exploratory Cold Study
- NCT number
- NCT01046136
- Phases
- PHASE2
- Conditions
- Common Cold
- Interventions
- guaifenesin (Mucinex), placebo
- Lead sponsor
- Reckitt Benckiser Inc.
- Results first posted
- 2012-08-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01046136?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01046136-c7749352